These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10412757)

  • 1. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients.
    Nishizawa Y; Shoji T; Tabata T; Inoue T; Morii H
    Kidney Int Suppl; 1999 Jul; 71():S134-6. PubMed ID: 10412757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
    Nishizawa Y; Shoji T; Emoto M; Kawasaki K; Konishi T; Tabata T; Inoue T; Morii H
    Clin Nephrol; 1995 Apr; 43(4):268-77. PubMed ID: 7606882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients.
    Oi K; Hirano T; Sakai S; Kawaguchi Y; Hosoya T
    Kidney Int Suppl; 1999 Jul; 71():S227-8. PubMed ID: 10412783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.
    Shoji T; Nishizawa Y; Kawagishi T; Tanaka M; Kawasaki K; Tabata T; Inoue T; Morii H
    Atherosclerosis; 1997 Jun; 131(2):229-36. PubMed ID: 9199276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherogenic lipoproteins in end-stage renal disease.
    Shoji T; Ishimura E; Inaba M; Tabata T; Nishizawa Y
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S30-3. PubMed ID: 11576918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
    Wanner C; Krane V
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S72-5. PubMed ID: 12612957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dyslipidemia in renal failure].
    Fujioka T; Ueno T; Matsumoto T; Watanabe H
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():118-23. PubMed ID: 15250280
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis.
    Siamopoulos KC; Elisaf MS; Bairaktari HT; Pappas MB; Sferopoulos GD; Nikolakakis NG
    Perit Dial Int; 1995; 15(8):342-7. PubMed ID: 8785232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency.
    Lee DM; Knight-Gibson C; Samuelsson O; Attman PO; Wang CS; Alaupovic P
    Kidney Int; 2002 Jan; 61(1):209-18. PubMed ID: 11786103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients.
    Llopart R; Doñate T; Oliva JA; Rodá M; Rousaud F; Gonzalez-Sastre F; Pedreño J; Ordoñez-Llanos J
    Nephrol Dial Transplant; 1995; 10(4):537-40. PubMed ID: 7623998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins for treatment of dyslipidemia in chronic kidney disease.
    Shurraw S; Tonelli M
    Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.
    Vega GL; Grundy SM
    Am J Cardiol; 1998 Feb; 81(4A):36B-42B. PubMed ID: 9526812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients.
    Ikejiri A; Hirano T; Murayama S; Yoshino G; Gushiken N; Hyodo T; Taira T; Adachi M
    Metabolism; 2004 Sep; 53(9):1113-7. PubMed ID: 15334369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the composition of plasma lipoproteins in the chronic uremic rat.
    Barry LE; Tan MH
    Atherosclerosis; 1990 Dec; 85(2-3):139-50. PubMed ID: 2102077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
    Bell DS
    Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.